Trials / Recruiting
RecruitingNCT06414759
Efficacy and Safety of Combination Diuretic Therapy in Patients With Acute Decompensated Heart Failure and Volume Overload
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 110 (estimated)
- Sponsor
- Cairo University · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to compare two medications, acetazolamide and metolazone, along with loop diuretics, to see which one works better and is safer for patients with ADHF who have volume overload. By comparing these medications, we hope to learn which one can help these patients the most. This will help doctors choose the best treatment for patients with ADHF and volume overload.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Acetazolamide | Acetazolamide is a medication that belongs to the class of carbonic anhydrase inhibitors. It acts by reducing the reabsorption of sodium in the proximal tubules of the kidneys. When combined with loop diuretics, acetazolamide has the potential to enhance the effectiveness of diuretic therapy, thus aiding in the process of decongestion. It will be given 500mg orally, once daily. |
| DRUG | Metolazone | Metolazone is a medication with properties like thiazide diuretics, prescribed for the management of congestive heart failure and hypertension. Its mechanism of action involves blocking the transport of sodium across the epithelium of renal tubules, predominantly in the distal tubules. It will be given 5mg orally, once daily. |
| DRUG | IV Loop Diuretics | IV loop diuretic 2 times the outpatient oral (PO) daily dose, and oral loop diuretics will be stopped. In cases where the patient was not previously on oral diuretics, a starting dose of 40 mg of IV furosemide, IV bumetanide 1 mg or a bolus of 20 mg of IV torsemide can be utilized. |
Timeline
- Start date
- 2024-07-01
- Primary completion
- 2024-12-30
- Completion
- 2025-03-30
- First posted
- 2024-05-16
- Last updated
- 2024-07-24
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT06414759. Inclusion in this directory is not an endorsement.